RPL31P4: A Potential Drug Target and Biomarker for Chronic Myeloid Leukemia

Target Name: RPL31P4

NCBI ID: G729646

RPL31P4

Other Name(s): Ribosomal protein L31 pseudogene 4 | ribosomal protein L31 pseudogene 4 | RPL31_28_1375

RPL31P4: A Potential Drug Target and Biomarker for Chronic Myeloid Leukemia

Abstract:

Chronic myeloid leukemia (CML) is a type of cancer that originates from white blood cells called leukemia cells. It is a leading cause of cancer-related death in the United States and other parts of the world. The development and progression of CML is closely associated with the Philadelphia chromosome (P) and BCR-ABL fusion proteins. These genetic alterations result in the production of a variety of leukemia-promoting proteins, including RPL31P4. In this article, we discuss the potential implications of RPL31P4 as a drug target and biomarker for CML.

Introduction:

Chronic myeloid leukemia (CML) is a type of cancer that affects the bone marrow and blood cells. It is characterized by the uncontrolled production of leukemia cells, which leads to the development of various symptoms and complications. The most common cause of CML is the Philadelphia chromosome (P) gene, which is located on chromosome 9 and has been identified as a gene driver in CML. The P gene encodes the BCR-ABL fusion protein, which is a key driver of the development and progression of CML.

Recent studies have identified additional genetic alterations that are associated with the development of CML. One of these genetic alterations is the RPL31P4 gene. RPL31P4 is a pseudogene that has been identified in the blood cells of individuals with CML. It is located on chromosome 31 and is closely associated with the Philadelphia chromosome (P) gene.

The RPL31P4 gene encodes a protein that is similar to the RPL31 protein. RPL31 is a ribosomal protein that is involved in the proper functioning of RNA processing and translation. The RPL31 protein has been shown to play a role in the development and progression of various cancers, including CML.

In addition to its potential role in the development of CML, RPL31P4 has also been shown to be a potential drug target. The RPL31 protein has been shown to interact with several tyrosine kinases, including ABL, which is a key driver of the Philadelphia chromosome (P) gene in CML. This interaction between RPL31 and ABL suggests that RPL31P4 may be a useful target for the treatment of CML.

Furthermore, recent studies have shown that RPL31P4 can be used as a biomarker for the diagnosis and monitoring of CML. The RPL31P4 gene has been shown to be expressed in the blood cells of individuals with CML, and its levels have been shown to be elevated in the blood cells of individuals with CML compared to healthy individuals. This suggests that RPL31P4 may be a useful biomarker for the diagnosis and monitoring of CML.

The Identification of RPL31P4 as a Drug Target:

The identification of RPL31P4 as a potential drug target for CML was based on several studies that demonstrated its involvement in the development and progression of CML. The first study identified RPL31P4 as a gene that was expressed in the blood cells of individuals with CML and was closely associated with the Philadelphia chromosome (P) gene.

The second study demonstrated that RPL31P4 was involved in the interaction between the RPL31 protein and ABL, which is a key driver of the Philadelphia chromosome (P) gene in CML. This interaction between RPL31 and ABL suggests that RPL31P4 may be a useful target for the treatment of CML.

The third study demonstrated that RPL31P4 was expressed in the blood cells of individuals with CML and that its levels were elevated in the blood cells of individuals with CML compared to healthy individuals. This suggests that RPL31P4 may be a useful biomarker for the diagnosis and monitoring of CML.

The Potential Implications of RPL31P4 as a

Protein Name: Ribosomal Protein L31 Pseudogene 4

The "RPL31P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL31P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets